GHS Cancer Institute has been awarded $6.7 million to conduct clinical trials and research studies aimed at improving patient outcomes and reducing health disparities. GHS is the only community-based site in S.C. to receive the award.
Clinical trials focus on improving cancer prevention, cancer control, screening for early cancers, and post-treatment surveillance. Cancer care delivery research will focus on quality of life and understanding the diverse and multi-level factors that affect access and quality of care.
[quote align=”center” color=”#999999″]“This grant is an affirmation and recognition of our ongoing efforts to find and develop innovative ways to improve all aspects of cancer care delivery. It’s also a vote of confidence in our ability to take research to the next level. GHS is among the best in the nation when it comes to cancer research, and the work that we do here will positively impact the lives of cancer patients in our community and beyond.” – Larry Gluck, medical director GHS Cancer Institute[/quote]
Cancer care in the last decade has made many advances. Most of these advances are the result of clinical research through clinical trials or research studies. Clinical trials have resulted in new treatments and prevention options for cancer care.
With a focus on translational research and personalized medicine, GHS’ Institute for Translational Oncology Research (ITOR) provides some of the most advanced cancer treatments available anywhere in the world, while supporting industry’s crucial need to achieve greater efficiency and expediency in bringing life-saving cancer drugs to patients. The effort to advance these dual goals was what led to the creation of ITOR in 2004.
ITOR is a major pillar of translational cancer research at GHS. The efforts of ITOR include a Phase I Clinical Research Unit, a Biorepository Services platform, and proteomics and enomics capabilities.
ITOR advances cancer care on multiple levels, facilitating pioneering research as well as clinical care delivery. ITOR is committed to translational medicine, which is a branch of medical research that forges a direct link between basic research and patient care. In the case of drug therapies, translational medicine refers to the translation of basic research into beneficial drug treatments for patients.
ITOR focuses on discovering and developing drugs that help people who have cancer.
The Cancer Moonshot Task Force focuses on making the most of federal investments, targeted incentives, private sector efforts from industry and philanthropy, patient engagement initiatives and other mechanisms to support cancer research and enable progress in treatment and care.
The national initiative, which brings together scientists, oncologists, donors and patients, is intended to galvanize efforts to double the pace of research toward curing cancer. The goal of the moonshot is to double the rate of progress toward a cancer cure – to essentially make a decade’s worth of advances in five years.
Some of the clinical trials discussed during the Moonshot Cancer Summit are already underway at GHS’ Cancer Institute and its Institute for Translational Oncology Research, which works closely with pharmaceutical innovators to develop and test new therapies.[quote align=”center” color=”#999999″]“Immunotherapy advances have tremendously accelerated over the past two years. While we’ve been able to fight cancer using tools like surgery, radiation and chemotherapy, we’ve only just begun to arrive at the point where we can activate the human body to take the fight directly to the cancer cells. The work being done now – nationwide and here – will be a game-changer.”
– Jeff Edenfield, MD, medical director of ITOR and the founder of GHS’ Rare Tumor Center.
GHS Human Performance Laboratory (HPL) is the first in the nation to be fully embedded into a cancer research and treatment program.
The HPL, which is working with a limited number of patients on a pilot basis, is a collaborative effort between Greenville Health System and the University of South Carolina School of Medicine Greenville. While its focus is on cancer survivor patients in the GHS Cancer Institute, the lab will ultimately serve all GHS clinical populations.
HPL traditionally have been the province of elite athletes who use the state-of-the-art analysis to improve performance. This the first time that an HPL has been used by a cancer institute to measure the changes in post-treatment cancer survivors — from whole body function all the way down the cellular level — in an effort to improve patient health and outcomes.
At GHS Cancer Institute, we are committed to research in understanding and eliminating barriers to accessing high-quality cancer care. Cancer Care Delivery Research (CCDR) improves clinical outcomes and patient well-being by improving patient, clinician, and organizational factors influencing care delivery. GHS’ CCDR team is comprised of doctors, nurses, and other health professionals committed to merging evidence-based cancer care with patients’ treatment preferences.
Leading the charge at GHS is Matthew F. Hudson, PhD, MPH. Dr. Hudson is the Director of Cancer Care Delivery Research (CCDR). He oversees initiatives examining how social factors, health care infrastructure, provider and patient behavior impact cancer care quality. He co-chaired the National Cancer Institute’s CCDR Coordinating Committee and presently co-chairs NRG Oncology’s CCDR committee. Dr. Hudson is also a research director for Greenville Health System’s Health Sciences Center (HSC)-a regional academic/health care collaborative informing sound clinical practice. Through the HSC, Dr. Hudson contributes to scholarship on patient-centered models of care, healthcare workforce education and development, health care access, and population health. Dr. Hudson holds faculty appointments at Clemson University, the University of South Carolina School of Medicine Greenville, and the Arnold School of Public Health (University of South Carolina). He teaches a course at the Arnold School entitled, “Comparative Effectiveness Research: Interface Opportunity for Public Health and Medicine”.
O’Rourke, M. A., O’Rourke, M. C., & Hudson, M. F. (2017). Reasons to Reject Physician Assisted Suicide/Physician Aid in Dying. Journal of Oncology Practice, 13(10), 683-686.
Jindal, M., Hudson, M. F., Blackhurst, D. W., Coltman, K., & McCoy, G. D. (2016).The Impact of Electronic Cues and Provider Education on Colorectal Cancer Screening. Referral and Patients’ Screening Decision Stage. Journal of the South Carolina Medical Association, 112(1), 169-171.
Russ-Sellers,R., Hudson, M.F., Youkey, J.R., & Horner, R.D. (2014). Achieving Effective Health Service Research Partnerships. Medical Care, 52(4), 289-290.
If you, or a loved one, have been diagnosed with cancer, you may want to consider participation in a clinical trial. Start your search by talking to your doctor.
Learn more about clinical trials supported by National Cancer Institute (NCI) in this brief video.